TAG Statement on Results of the PreVenTB Phase III Trial of TB Vaccine Candidates VPM1002 and Immuvac
Well-conducted study sponsored by Indian Council of Medical Research did not meet primary efficacy endpoint of preventing microbiologically confirmed TB disease
